| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
2 companies
Proquest Investments IV, L.P. last filed a Form 4 in November 2017, as 10% Owner at URGN. The filings on record cover 2 companies.
At the last filing, the largest reported position was 1,242,031 shares of URGN. The URGN filings lean toward selling, a net 209,298 shares.
Proquest Investments IV, L.P. has 17 Form 4 filings on record from August 2016 to November 2017, across 2 companies: 10% Owner at UroGen Pharma (URGN), 2017; 10% Owner at Eagle Pharmaceuticals (EGRX), 2016–2017.
The 86 reported transactions were 74 open-market sales, 9 option exercises and 3 other transactions.
Counted by filing, the open-market trades come to no purchases and 16 sales worth about $102.1M.
The largest open-market sale was 245,770 shares of EGRX at an average $71.02 on November 4, 2016, about $17.5M.
Shares as reported in the last Form 4 for each company; the most recent is from November 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2017 | URGN Urogen Pharma Ltd. | 10% Owner | Sell | 209,298 | $40.60 | $8,497,871.49 | -14.4% | |
| Apr 25, 2017 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sale+OE | 54,180 | $88.38 | $4,788,481.95 | -88.9% | |
| Apr 3, 2017 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 91,332 | $83.09 | $7,589,014.38 | -2.5% | |
| Mar 29, 2017 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 106,468 | $83.01 | $8,837,576.19 | -82.1% | |
| Mar 23, 2017 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 1,200 | $83.05 | $99,657.00 | - | |
| Mar 20, 2017 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 100,000 | $82.06 | $8,206,307.87 | -2.6% | |
| Jan 4, 2017 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 65,114 | $85.16 | $5,545,108.24 | -1.7% | |
| Nov 11, 2016 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 34,486 | $85.15 | $2,936,604.80 | -0.9% | |
| Nov 9, 2016 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 153,830 | $79.29 | $12,197,276.85 | -3.7% | |
| Nov 4, 2016 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 245,770 | $71.02 | $17,455,384.89 | -5.6% |